English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Aim  Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the development of diagnostic, prognostic and predictive biomarkers in human cancer, including colorectal cancer (CRC). The aim of this study was to perform a systematic and comprehensive analysis of a panel of CRC-specific genes as potential diagnostic, prognostic and predictive biomarkers in a large, population-based CRC cohort.    Patients and Methods  Methylation status of the  SEPT9, TWIST1, IGFBP3, GAS7, ALX4 and miR137  genes was studied by quantitative bisulfite pyrosequencing in a population-based cohort of 425 CRC patients.    Results  Methylation levels of all genes analyzed were significantly higher in tumor tissues compared to normal mucosa (p<0.0001); however, cancer-associated hypermethylation was most frequently observed for  miR137  (86.7%) and  IGFBP3  (83%) in CRC patients. Methylation analysis using the combination of these two genes demonstrated greatest accuracy for the identification of colonic tumors (sensitivity 95.5%; specificity 90.5%). Low levels of  IGFBP3  promoter methylation emerged as an independent risk factor for predicting poor disease free survival in stage II and III CRC patients (HR = 0.49, 95% CI: 0.28–0.85, p = 0.01). Our results also suggest that stage II & III CRC patients with high levels of  IGFBP3  methylation do not benefit from adjuvant 5FU-based chemotherapy.    Conclusion  By analyzing a large, population-based CRC cohort, we demonstrate the potential clinical significance of  miR137  and  IGFBP3  hypermethylation as promising diagnostic biomarkers in CRC. Our data also revealed that  IGFBP3 hyper methylation may serve as an independent prognostic and predictive biomarker in stage II and III CRC patients.

IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal Cancer